Refractory vasculitis

Autoimmun Rev. 2011 Sep;10(11):702-6. doi: 10.1016/j.autrev.2011.04.024. Epub 2011 May 11.

Abstract

Refractory vasculitis occurs in 4-5% of patients with anti-neutrophil cytoplasmic antibody associated vasculitis (AAV). Differences between therapies used for refractory disease are mostly reflected in the percentages of complete and partial remissions, but also in the number of serious side effects. Rituximab is considered the most safe second line therapy and should be advocated as a first alternative choice for cyclophosphamide in disease induction in refractory AAV.

Publication types

  • Review

MeSH terms

  • Antibodies, Antineutrophil Cytoplasmic / blood
  • Antibodies, Antineutrophil Cytoplasmic / immunology
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use*
  • Clinical Trials as Topic
  • Cyclophosphamide / therapeutic use
  • Disease Progression
  • Drug Resistance
  • Evidence-Based Medicine
  • Humans
  • Recurrence
  • Rituximab
  • Vasculitis / diagnosis*
  • Vasculitis / immunology
  • Vasculitis / physiopathology
  • Vasculitis / therapy*

Substances

  • Antibodies, Antineutrophil Cytoplasmic
  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab
  • Cyclophosphamide